ライフサイエンスコーパス: joint disease

1 decrease of the lubrication in degenerative joint disease.

2 in alone is sufficient to drive inflammatory joint disease.

3 cytokine-independent mechanisms involved in joint disease.

4 determined TSG-6 expression in inflammatory joint disease.

5 ammation and tissue destruction in arthritic joint disease.

6 c factors, autoantibodies, inflammation, and joint disease.

7 nd cartilage degradation during degenerative joint disease.

8 ture study of inflammation in this prevalent joint disease.

9 for therapeutic intervention in inflammatory joint disease.

10 ether IL-23-induced skin inflammation drives joint disease.

11 rthritis or osteoarthritis, or those without joint disease.

12 plicated in the pathogenesis of inflammatory joint disease.

13 estruction of connective tissue resulting in joint disease.

14 may be an effective therapy for degenerative joint disease.

15 el therapeutics for the treatment of chronic joint disease.

16 m by which antibodies to GPI may precipitate joint disease.

17 cessfully treated infections or degenerative joint disease.

18 nd may serve as an indicator of degenerative joint disease.

19 evolution of this condition to degenerative joint disease.

20 turbances in these processes are involved in joint disease.

21 3 patients (78%) had persistent inflammatory joint disease.

22 e and fluid-and subsequently contributing to joint disease.

23 e, joint laxity and early-onset degenerative joint disease.

24 ggested an entheseal-based pathology for the joint disease.

25 denstrom's macroglobulinemia who do not have joint disease.

26 window into the pathogenesis of inflammatory joint disease.

27 by it can potentially initiate or accelerate joint disease.

28 , and in cartilage from adults with no known joint disease.

29 joints and hip, but the runners had more PF joint disease.

30 cts in initiating or amplifying inflammatory joint disease.

31 ue to limited understanding of OA as a whole-joint disease.

32 n inflammation may represent a key driver of joint disease.

33 oint space width distribution and structural joint disease.

34 n that causes debilitating acute and chronic joint disease.

35 o significantly associated with degenerative joint disease.

36 dered in patients with psoriatic skin and/or joint disease.

37 thritis (OA) is the most common degenerative joint disease.

38 Osteoarthritis (OA) is the most common joint disease.

39 Osteoarthritis is a common progressive joint disease.

40 Osteoarthritis is a complex degenerative joint disease.

41 cardiovascular remodeling, and degenerative joint disease.

42 hemophilic arthropathy (HA), a debilitating joint disease.

43 ased PLV-LMC turnover during amelioration of joint disease.

44 tis (OA) is a low-grade chronic inflammatory joint disease.

45 therapeutic target for treating degenerative joint disease.

46 resolvins (RvTs), and significantly reduced joint disease.

47 c phenotype may protect against degenerative joint disease.

48 aetiology and possible treatment of synovial joint disease.

49 hemarthroses can prevent the development of joint disease.

50 drome of autoimmunity manifested by lung and joint disease.

51 ly in macrophages, ameliorated both skin and joint disease.

52 atic arthritis or unmasked previously occult joint disease.

53 ) is an age-related progressive degenerative joint disease.

54 ental animal model of immune complex-induced joint disease.

55 ent of debilitating psoriatic arthritis-like joint disease.

56 s (OA), a chronic and degenerative articular joint disease.

57 gnal in driving adaptive immunity in erosive joint disease.

58 g complications and progression to end-stage joint disease.

59 plicated in the pathogenesis of inflammatory joint disease.

60 idiopathic arthritis among the inflammatory joint diseases.

61 es for non-rheumatoid arthritis inflammatory joint diseases.

62 with other inflammatory and noninflammatory joint diseases.

63 potentially treat degenerative/inflammatory joint diseases.

64 n of the cartilage phenotype in inflammatory joint diseases.

65 ate cartilage mineralization in degenerative joint diseases.

66 ction that is characteristic of inflammatory joint diseases.

67 ly event in the pathogenesis of degenerative joint diseases.

68 n, in a way that is different from all other joint diseases.

69 her development of gene treatments for human joint diseases.

70 s play critical roles in the pathogenesis of joint diseases.

71 , spondyloarthropathies, and other arthritic joint diseases.

72 to the onset and progression of inflammatory joint diseases.

73 function in patients with degenerative knee joint diseases.

74 ed in tumor angiogenesis and in inflammatory joint diseases.

75 new physical or pharmacologic therapies for joint diseases.

76 ation-induced microparticles in inflammatory joint diseases.

77 ociated comorbidities were 6/14 degenerative joint disease, 9/10 gastroesophageal reflux disorder, 2/

78 Osteoarthritis is a chronic and progressive joint disease accompanied by cartilage degeneration and

79 RA activity was assessed using the 28-joint Disease Activity Score (DAS-28).

80 regression analyses adjusted for baseline 28 joint disease activity score (DAS28), baseline health as

81 her serum ACPA concentration (P = 0.004), 28-joint Disease Activity Score (P = 0.023), health assessm

82 int counts and the activity scores on the 28-joint Disease Activity Score assessment.

83 aire-Disability Index (HAQ-DI) score, the 28-joint Disease Activity Score based on C-reactive protein

84 achieving low disease activity defined as 28-joint Disease Activity Score using C-reactive protein (D

85 d the stable low disease activity target (28-joint disease activity score with C-reactive protein [DA

86 ge of Rheumatology 20% response criteria, 28-joint Disease Activity Score, DeltaHAQ, DeltaRAQoL, and

87 graphic and functional outcomes, although 28-joint Disease Activity Score-based measures of remission

88 ine kinase (CK) level, as well as muscle and joint disease activity.

89 r a patient with significant nail, skin, and joint disease, adalimumab, etanercept, ustekinumab, infl

90 nd with adjacent synovium plays key roles in joint disease affecting local inflammatory responses.

91 teoarthritis (OA) is a complex heterogeneous joint disease affecting more than 35 million people worl

92 arthritis (OA) is a chronic and degenerative joint disease affecting more than 500 million patients w

93 OA is the most common joint disease, affecting 10-15% of people over 60 years

94 Osteoarthritis (OA) is the most common joint disease, affecting an estimated more than 240 mill

95 Degenerative joint disease, also known as osteoarthritis, is the most

96 Osteoarthritis is the most common type of joint disease among elderly patients around the world.

97 y levels correlated modestly with muscle and joint disease, an association confirmed by a custom ELIS

98 with early RA with clinically diagnosed MCP joint disease and 28 healthy controls were examined by m

99 Osteoarthritis is the most prevalent joint disease and a common cause of joint pain, function

100 Osteoarthritis is the most prevalent joint disease and a frequent cause of joint pain, functi

101 Osteoarthritis is a prevalent joint disease and a major cause of disability worldwide

102 OA is a whole joint disease and affects both cartilage and the underly

103 to virus-host interactions and mechanisms of joint disease and connective tissue disease.

104 Osteoarthritis (OA) is the most common joint disease and involves progressive degeneration of a

105 Osteoarthritis (OA) is the most common whole-joint disease and is characterized by progressive loss o

106 Degeneration is a hallmark of painful joint disease and is mediated by many proteases that deg

107 rapidly developed rheumatoid arthritis-like joint disease and large-vessel vasculitis.

108 ially used for the treatment of inflammatory joint disease and only later in the treatment of inflamm

109 of an effective therapy in the treatment of joint disease and other pathologies involving the action

110 ckade in a therapeutic model of inflammatory joint disease and provide support for pursuing this ther

111 The syk(f/f) MRP8-cre(+) mice display absent joint disease and reduced deposition of pathogenic anti-

112 synovitis could develop in both degenerative joint disease and spondylarthritis.

113 rtant role of TLR4 signaling in MPS bone and joint disease and suggest that targeting TNF-alpha may h

114 proliferative changes observed in hemophilic joint disease and that aberrant expression of c-myc may

115 Osteoarthritis (OA) is the most common joint disease and typically begins with an aging-related

116 RA is an inflammatory joint disease and, compared with the general population,

117 in the treatment of a number of inflammatory joint diseases and have been widely available in clinica

118 in which surviving mice acquire degenerative joint diseases and tumors in multiple organs.

119 es mellitus, hypogonadotrophic hypogonadism, joint disease, and cardiomyopathy.

120 thritis (RA) is the most common inflammatory joint disease, and early diagnosis is key for effective

121 Osteoarthritis (OA) is a degenerative joint disease, and inflammation within an arthritic join

122 r patents tend to manifest enthesitis, axial joint disease, and persistent oligoarthritis.

123 pathway in the pathogenesis of MPS bone and joint disease, and the use of the anti-TNF-alpha drug, R

124 (OA) is the most prevalent and debilitating joint disease, and there are currently no effective dise

125 clinical efficacy of adrenocorticotropin in joint diseases, AP1189 was tested in experimental inflam

126 we observe no clinical signs of degenerative joint disease apart from mild, or in one case moderate,

127 he factors that control T cell activation in joint disease are not well understood.

128 The manifestations of joint disease are usually clinically apparent, but the e

129 Joint diseases are often characterized by inflammatory p

130 s, genitals, face, or nails, and concomitant joint disease, are also important when considering treat

131 f complete understanding of how inflammatory joint disease arises and progresses.

132 ition in the treatment of psoriatic skin and joint disease as well as inflammatory bowel diseases.

133 ment, breakthrough bleeding, and progressive joint disease, as well as high rates of inhibitor develo

134 ne cells play a central role in degenerative joint disease associated with osteoarthritis (OA) and pa

135 NSAID) robenacoxib in cats with degenerative joint disease-associated pain (DJD-pain).

136 arthritis (RA), the most severe inflammatory joint disease, autoantibodies against citrullinated prot

137 rogression of osteoarthritis, a debilitating joint disease causing cartilage degeneration.

138 Osteoarthritis is a joint disease characterized by a nonsymptomatic, preradi

139 Osteoarthritis is a degenerative joint disease characterized by a progressive and irrever

140 Osteoarthritis (OA) is the leading joint disease characterized by cartilage destruction and

141 Psoriatic arthritis (PsA) is an inflammatory joint disease characterized by extensive bone resorption

142 Osteoarthritis (OA) is the most common joint disease characterized by joint inflammation and ca

143 Osteoarthritis (OA) is a debilitating joint disease characterized by progressive cartilage deg

144 Osteoarthritis (OA) is a common joint disease characterized by progressive loss of carti

145 Gout is a common autoinflammatory joint diseases characterized by deposition of monosodium

146 Osteoarthritis (OA) is a common degenerative joint disease, characterized by cartilage loss and subch

147 of clinics marketing stem cell products for joint diseases, chronic pain, and most recently, COVID-1

148 the severity of autoimmune and inflammatory joint disease correlates with large numbers of CD4+CD28-

149 aneously triggers both psoriasiform skin and joint disease, demonstrating a crucial role for epiderma

150 Patients with liver disease, joint disease, diabetes mellitus and other endocrinopath

151 Secondary end points were measures of joint disease, disability, and quality of life in all pa

152 TMJ) disc displacement (DD) and degenerative joint disease (DJD) has never been conclusively describe

153 (AI) model for the screening of degenerative joint disease (DJD) using temporomandibular joint (TMJ)

154 t reduction (DDwR and DDwoR) to degenerative joint disease (DJD), and patient-reported outcomes of ja

155 In osteoarthritic joint disease, expression of bFGF and MMP-13 in chondroc

156 Osteoarthritis is a common degenerative joint disease for which no disease-modifying drugs are c

157 Osteoarthritis (OA) is a widespread joint disease for which there are no disease-modifying t

158 Chronic joint disease from repeated bleeding into joints is a se

159 dity in these patients included degenerative joint disease, gastroesophageal reflux disease, hyperten

160 major role in the pathogenesis of hemophilic joint disease (HJD).

161 hibitors have proved effective in rheumatoid joint disease; however, their effect on the tenosynovium

162 tes, a cell type central to the pathology of joint diseases, immune-evasive saRNA enables sustained t

163 inumab for treatment of psoriatic arthritis, joint disease improved.

164 gh very effective, do not completely prevent joint disease in a long-term perspective.

165 pain symptoms, disability, and more serious joint disease in American Indian patients.

166 the development of autoimmune, inflammatory joint disease in animals that are susceptible to the dev

167 d immunomodulator affords protection against joint disease in collagen-induced arthritis, a mouse mod

168 ameliorated the development of inflammatory joint disease in mice challenged with collagen-induced a

169 as a potential novel therapeutic target for joint disease in RA with potential for vascular benefit,

170 ew treatments have been developed to control joint disease in rheumatoid arthritis, they are partiall

171 ern that ustekinumab may unmask or aggravate joint disease in selected patients.

172 Joint disease in Smad3-knockout (Smad3(-/-)) mice was ex

173 c therapies in the treatment of degenerative joint disease in the future.

174 ight into the complex processes that mediate joint disease in the inflammatory arthritides through th

175 Osteoarthritis is the most common joint disease in the world with significant societal con

176 arthritis (RA) is an inflammatory autoimmune joint disease in which the complement system plays an im

177 trogens may ameliorate bone and inflammatory joint diseases in patients infected with HTLV-I by repre

178 h changes might mimic prevalent degenerative joint diseases in the elderly.

179 useful information that may help understand joint diseases in the general population and how therapi

180 nd with adjacent synovium plays key roles in joint disease including the production of Substance P (S

181 inct regulatory roles in the pathogenesis of joint diseases including osteoarthritis (OA) and rheumat

182 ons contribute to the progression of several joint diseases, including knee osteoarthritis (KOA).

183 tionship with meniscal tear and degenerative joint disease independent of effusion was also demonstra

184 significant association between severity of joint disease, induced with distinct protocols and volum

185 litions also can be acquired by degenerative joint disease, inflammatory arthritis, infection, and cl

186 s, and one mechanism linking fibrin(ogen) to joint disease is coupled to alphaMbeta2-mediated inflamm

187 e both with and without chronic inflammatory joint disease is emerging.

188 with clinical problems, but the severity of joint disease is only weakly related to that of the clin

189 The end stage of inflammatory joint diseases is characterized by excessive ECM catabol

190 rthritis (OA), the most common aging-related joint disease, is caused by an imbalance between extrace

191 ritis (OA), the most prevalent aging-related joint disease, is characterized by insufficient extracel

192 ajor concern due to the debilitating chronic joint disease it causes.

193 s most commonly associated with inflammatory joint diseases, it also occurs in OA and is thus relevan

194 mobilization is therapeutic for inflammatory joint diseases like rheumatoid and osteoarthritis, but t

195 This suggests that the anatomic basis for joint disease localization differs between RA and PMR.

196 The anatomic basis for joint disease localization in polymyalgia rheumatica (PM

197 is and rheumatoid arthritis are debilitating joint diseases marked by pain, inflammation and cartilag

198 previous 6 months (mCSA), temporomandibular joint disease (mCSA and section modulus), functional dis

199 of disease between patients with neuropathic joint disease (NJD) and patients with degenerative arthr

200 ecruited at New York University Hospital for Joint Diseases (NYUHJD), and 1 cohort (a validation coho

201 tic manifestations of osteoarthrosis (OA), a joint disease of major economic importance.

202 ndon, enthesis, and adjacent bone in the DIP joint disease of PsA patients.

203 flammation (100%) experienced improvement in joint disease, only 6 of 16 with ocular inflammation (38

204 descriptors did not distinguish the type of joint disease or pain intensity.

205 ere will be fewer joint bleeds, debilitating joint disease, orthopedic surgery, and improved physical

206 contribution of inflammation to the chronic joint disease osteoarthritis (OA) is unclear, and this l

207 As the most common degenerative joint disease, osteoarthritis (OA) contributes significa

208 The pathophysiology of the most common joint disease, osteoarthritis (OA), remains poorly under

209 own as Post-Chikungunya Chronic Inflammatory Joint Disease (pCHIKV-CIJD).

210 on the development of Ag-driven inflammatory joint disease, possibly by mediating the recruitment and

211 Although it is not clear whether joint disease precedes or follows a decline in muscular

212 bricin degradation occurring in inflammatory joint diseases predisposes the cartilage to damage.

213 one of the most common and most debilitating joint diseases, producing high personal, social, and eco

214 and the role of macrophages in inflammatory joint disease remain unclear.

215 opment of acute and chronic CHIKV-associated joint disease remains poorly understood.

216 mmation, which might improve on treatment of joint disease, remains to be determined.

217 sculoskeletal and Skin Diseases/Hospital for Joint Diseases Research Registry for Neonatal Lupus.

218 on 8 (Smad3(ex8/ex8)) developed degenerative joint disease resembling human osteoarthritis, as charac

219 n and results in development of degenerative joint disease resembling osteoarthritis in humans.

220 itis (OA) is the most prevalent degenerative joint disease, resulting in joint pain, impaired movemen

221 nalysis of the different stages of arthritic joint disease revealed enhanced (18)F-FLT uptake in arth

222 or the treatment of the chronic inflammatory joint disease rheumatoid arthritis has reinvigorated res

223 antagonist RNase1 in a chronic inflammatory joint disease, rheumatoid arthritis (RA).

224 Serum COMP levels correlated with total-body joint disease severity as determined by late-phase bone

225 adian rhythm disruption is a risk factor for joint diseases such as OA.

226 meostasis and its disturbance contributes to joint diseases such as osteoarthritis (OA).

227 es and therapeutic interventions for chronic joint diseases such as osteoarthritis and rheumatoid art

228 to improved treatment modalities for common joint diseases such as osteoarthritis, and indicate how

229 tion of the cartilage matrix in degenerative joint diseases such as osteoarthritis.

230 of the cartilage matrix during degenerative joint diseases such as osteoarthritis.

231 from articular cartilage during degenerative joint diseases such as osteoarthritis.

232 differentiation and may have implications in joint diseases such as osteoarthritis.

233 The onset of degenerative joint diseases such as post-traumatic osteoarthritis (PT

234 atment may reduce the burden of inflammatory joint diseases such as rheumatoid arthritis by facilitat

235 t common effector mechanisms in inflammatory joint diseases such as rheumatoid arthritis.

236 py offers a novel approach to treating human joint diseases such as rheumatoid arthritis.

237 l treatment of inflammatory and degenerative joint disease, such as osteoarthritis and rheumatoid art

238 Degenerative joint diseases, such as arthritis, cause loss of normal

239 The hallmark of joint diseases, such as osteoarthritis (OA), is pain, or

240 ion as diagnostic and therapeutic agents for joint diseases, such as osteoarthritis.

241 ontributes to cartilage loss in inflammatory joint diseases, such as rheumatoid arthritis (RA).

242 at refractory synovitis in many inflammatory joint diseases, such as rheumatoid arthritis, spondyloar

243 ch as age and sex; description of ocular and joint disease; surgical and other complications; medical

244 nsion, gastroesophageal reflux, degenerative joint disease symptoms, type 2 diabetes mellitus, pseudo

245 nd controls (non-Lyme arthritis inflammatory joint disease, syphilis, multiple sclerosis, and nondise

246 esses are better documented for inflammatory joint diseases than tendinopathy even though the pathoge

247 Osteoarthritis is a heterogeneous whole-joint disease that can cause pain and is a leading cause

248 Osteoarthritis is a degenerative joint disease that causes pain, degradation, and dysfunc

249 Osteoarthritis (OA) is a highly prevalent joint disease that causes substantial disability, yet ef

250 ent in rheumatoid arthritis, an inflammatory joint disease that disables millions of people worldwide

251 Rheumatoid arthritis (RA) is an inflammatory joint disease that eventually leads to permanent bone an

252 ant Lyme arthritis is a chronic inflammatory joint disease that follows infection with Borrelia burgd

253 Osteoarthritis (OA) is a chronic joint disease that has long been considered a simple wea

254 al proinflammatory cytokine for inflammatory joint disease that integrates fibroblast activation with

255 Osteoarthritis (OA) is a degenerative joint disease that involves the destruction of articular

256 e osteoarthritis is a highly prevalent whole-joint disease that is associated with substantial morbid

257 Osteoarthritis is a degenerative joint disease that ranks among the leading causes of adu

258 ght new therapeutic targets for inflammatory joint diseases that aim to repress the expression of col

259 fluence on progenitor cells for degenerative joint disease therapies.

260 ation, gastroesophageal reflux, degenerative joint disease, urinary incontinence, venous stasis, and

261 Degenerative joint disease was more prevalent in the super-elderly gr

262 Although joint disease was prevented or cured in five of five amo

263 the effect of TSG-6 on chronic inflammatory joint disease, we induced CIA in DBA/1J mice by immuniza

264 llows concurrent assessment of both skin and joint disease, we showed that CCR6 is critical for infla

265 ukocyte protease inhibitor (SLPI) in erosive joint diseases, we cloned, sequenced, and expressed acti

266 ither inflammatory eye disease or associated joint disease were studied retrospectively to determine

267 (OA) is the most common chronic degenerative joint disease which causes substantial joint pain, defor

268 ic arthritis (PsA) is a chronic inflammatory joint disease which develops in patients with psoriasis.

269 Degenerative joint disease, which affects one-fifth of the US populat

270 eumatoid arthritis is a chronic inflammatory joint disease, which can cause cartilage and bone damage

271 ombination leads to early onset degenerative joint disease, which is revealed by simultaneous enlarge

272 Osteoarthritis is a degenerative joint disease whose molecular mechanism is currently unk

273 (OA) is a prevalent, heritable degenerative joint disease with a substantial public health impact.

274 Osteoarthritis (OA) is a joint disease with an etiology partially rooted in metab

275 oid arthritis (RA) is a chronic inflammatory joint disease with episodic flares.

276 K/BxN mice develop an inflammatory joint disease with many features characteristic of rheum

277 ressing tmTNF developed axial and peripheral joint disease with synovitis, enthesitis, and osteitis.

278 oid arthritis (RA) is one of the major human joint diseases with unknown etiology, the early diagnosi

279 rmation regarding how these pathogens elicit joint disease, with emphasis on C. trachomatis in its ro

280 phils protected wild-type mice from skin and joint disease without suppressing T helper type 17 cytok

281 Osteoarthritis is the most prevalent joint disease worldwide, yet progress in development of

282 and rheumatoid arthritis (RA) are prevalent joint diseases, yet early diagnosis remains challenging